TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

XEPI

OZENOXACIN
Approved 2017-12-11
1
Indication
--
Phase 3 Trials
8
Years on Market

Details

Status
Discontinued
First Approved
2017-12-11
Routes
TOPICAL
Dosage Forms
CREAM

Companies

Active Ingredient: OZENOXACIN

XEPI Approval History

Loading approval history...

What XEPI Treats

1 FDA approvals

Originally approved for its first indication in 2017 .

  • Other (1)
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

XEPI FDA Label Details

Pro

XEPI Patents & Exclusivity

Latest Patent: Jan 2032

Patents (2 active)

US9180200 Expires Jan 29, 2032
US9399014 Expires Dec 15, 2029
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.